Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
122 people get SCR articles and Market Currents by email alert.
Get email alerts on SCR »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
Simcere Wins Approval for Anti-Nausea Drug, Reports Disappointing Q2ChinaBio Today • Fri, Aug 13, 2010
-
-
-
-
Operations of Simcere's Latest Acquisition Remain Shut DownChinaBio Today • Mon, Apr 5, 2010
-
Simcere's Cancer Drug Makes Significant Headway in TrialsChinaBio Today • Tue, Mar 23, 2010
-
Simcere Wins OK for Flu Drug RelenzaChinaBio Today • Fri, Feb 12, 2010
-
-
Simcere Acquires Statin Manufacturing LicenseChinaBio Today • Tue, Nov 10, 2009
-
-
Simcere Teams Up with Cancer Center to Develop DrugsChinaBio Today • Tue, Aug 25, 2009
-
Simcere Pharma Follows Diversified Expansion StrategyChinaBio Today • Wed, May 27, 2009
-
Simcere's Q1 Disappoints InvestorsChinaBio Today • Wed, May 20, 2009
-
-
Simcere's Q4: Revenues Up, Earnings DownChinaBio Today • Fri, Mar 13, 2009
-
Simcere Issues Net Income Warning for 2008ChinaBio Today • Tue, Jan 13, 2009
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
Merck Successes Create Buying OpportunityValueMax • Wed, Oct 10, 2012 -
-
-
-
-
Hedge Funds Love These 12 Chinese StocksKapitall • Mon, Jan 30, 2012
-
Hedge Funds Are Buying Up These 20 Healthcare StocksKapitall • Thu, Jan 26, 2012
-
-
Hedge Funds Are Buying These 20 BRIC StocksKapitall • Thu, Jan 5, 2012
-
10 Chinese Stocks For Profits In 2012, Part IIStock Croc • Fri, Dec 30, 2011 -
-
PR Newswire (May 29, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (Apr 27, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Apr 3, 2013)
-
PR Newswire (Mar 22, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Mar 11, 2013)
-
Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 ResultsPR Newswire (Mar 7, 2013)
-
PR Newswire (Jan 22, 2013)
-
PR Newswire (Nov 15, 2012)
-
PR Newswire (Oct 12, 2012)
-
PR Newswire (Sep 13, 2012)
-
PR Newswire (Aug 10, 2012)
-
PR Newswire (Jul 30, 2012)
-
PR Newswire (May 11, 2012)
SCR vs. ETF Alternatives
Company Description
Currently, there's no company description for SCR.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 6:42 AM Simcere Pharmaceuticals (SCR): Q1 EPS of $0.09 beats by $0.01. Revenue of $85.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Monday, March 11, 12:56 PM
Midday top 10 gainers: CALI +52%. BOSC +45%. ESYS +30%. CBMX +25%. LAS +25%. PAMT +15%. FONR +15%. SCR +15%. SGOC +15%. RWC +14%.
Midday top 10 losers: AEZS -21%. NSU -11%. CSIQ -11%. SPEX -11%. FREE -10%. DKS -10%. CERE -10%. CNIT -9%. ONP -9%. RDCM -8%. Comment! [On the Move] - Monday, March 11, 8:29 AM Simcere Pharmaceutical (SCR) jumps 16.2% to $9.25 after the Chinese company receives a buyout offer of $9.56/ADS from a consortium led by its chairman, Jinsheng Ren. The bid represents a premium of 19% on Simcere's Friday close of $7.96 and values the firm at $500M. The firm has appointed a committee of independent directors to analyze the offer. (PR) Comment! [Healthcare, On the Move, M&A]
- Thursday, March 7, 2:37 PM Simcere Pharmaceutical (SCR -0.3%) slips after reporting a Q4 loss of $0.06 per ADS, versus flat consensus estimates, primarily due to a non-cash impairment charge of as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi Biological Technology. Gross margin also fell to 81.1%, compared to 82.3%. Read more on earnings here: Earnings Call Transcript. Comment! [Healthcare, Earnings]
- Thursday, March 7, 5:29 AM Simcere Pharmaceutical (SCR): Q4 Preliminary EPS of -$0.06. Preliminary Revenue of $86.7M (+5.7% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, November 15, 2012, 6:52 AM Simcere Pharmaceutical (SCR): Q3 EPS of $0.07. Revenue of $83.8M (+5.1% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Friday, August 10, 2012, 5:52 AM Simcere Pharmaceutical (SCR): Q2 EPS of $0.04 misses by $0.06. Revenue of $83.2M (-1.4% Y/Y) misses by $3M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, May 9, 2012, 6:03 AM Simcere Pharmaceutical (SCR): Q1 EPS of $0.08 in-line. Revenue of $77.4M (+5.2% Y/Y) misses by $7M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, March 7, 2012, 7:43 AM Simcere Pharmaceutical (SCR): Q4 EPS of $0.12 beats by $0.07. Revenue of $81.2M (-9.2% Y/Y) misses by $6M. (PR) Comment! [Earnings, Healthcare]
- Monday, November 16, 2009, 12:05 AM Notable premarket earnings: LOW, PWRD, SOL, SCR Comment!